Taiwan Liposome Company, Ltd. — key financial figures for fiscal year 2020 (in USD), standardized from XBRL/iXBRL filings by Hub-Equity:

Revenue (FY2020)

$101.9M

Net Income/Loss (FY2020)

-$983.3M

Total Assets (FY2020)

$62.3M

Total Equity (FY2020)

$863.3M

Cash Flows from Operating Activities (FY2020)

-$31.2M

Source: Taiwan Liposome Company, Ltd. 20-F filing (FY2020). Full income statement, balance sheet and cash flow, restatement-aware and traceable to the source filing, at Hub-Equity.